Elevation Oncology Long Term Debt

Elevation Oncology (ELEV) currently reports a long-term debt of $0 as of March 2025. That compares with $31M in the prior-year period — down 100.0% year over year. Use the charts on this page to explore Elevation Oncology's long-term debt history and peer comparisons.

Elevation Oncology's long-term debt decreased from $31M to $0 — a 100.0% year-over-year decrease (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Elevation Oncology reported $0 in long-term debt as of March 2025. That compares with $31M in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Elevation Oncology, and consider following ELEV for alerts when major investors trade the stock.

Elevation Oncology is classified in the Healthcare sector. On long-term debt, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ELEV with unrelated industries.